1. Bond CA, Raehl CL. Pharmacist provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications and transfusions. Pharmacother 2004;24:953–63.
2. Yen YH, Chen HY, Wuan-Jin L, et al. Clinical and economic impact of a pharmacist-managed iv-to-po conversion service for levofloxacin in Taiwan. Int J Clin Pharmacol Ther 2012;50:136–41.
3. Buyle F, Vogelaers D, PelemanR, et al. Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospital. Pharm World Sci 2010;32:404–10.
4. Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic consideration associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia Clin Infect Dis 2005;41Supp2;5:136–43.
5. Ho BP, Lau TT, Balen RM, et al. The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: a pre- and post-intervention study. BMC Health Serv Res 2005;5:48.
6. Kuti JL, Le TN, Nightingale CH, et al. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from iv to oral. Am J Health Sys Pharm 2002;59:2209–15.
7. Cohen SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000;232:254–62.
8. Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000;44:1796–802.
9. Wetzstein GA. Intravenous to oral (IV:PO) anti-infective combination therapy. Cancer Control 2000;7:170–6.
10. Paladino JA. Pharmacoeconomics of antimicrobial therapy. Am J Healthsys Pharm 1999;56(Supp3):S25–8.
11. Ahkee S, Smith S, et al. Early switch from intravenous to oral antibiotics in hospitalized patient with infections: a six-month prospective study. Pharmacotherapy 1997;17:569–75.
12. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 1997;17:271–6.
13. Jewesson P. Cost-effectiveness and value of an IV switch. Pharmacoeconomics 1994;5(Supp2):20–6.
14. Ramirez J. Advances in antibiotic use: switch therapy. Curr Ther Res 1994;55(suppA):30–3.
15. Shepard MF. Making the switch from IV to PO. Am J Healthsys Pharm 1994;50:2510.
16. Chessin LN. When to switch from IV to oral antibiotics. Patient Care 1993;15:113–25.
17. Cohen MR. Important news! IV route not needed to justify hospitalization for antibiotics. Hospital Pharmacy 1993;28:946.
18. Schentag JJ. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, infectious disease division and the microbiology laboratory. Diagnos Microbiol Infect Dis 1993;16:255–64.
19. Fighetto L. Intravenous to oral stepdown program: four years’ experience in a large teaching hospital. Ann Pharmacother 1992;26:1447–51.
20. Powers T. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy. Am J Healthsys Pharm 1990;47:1781–4.
21. Ament PW, McGuire WM. Setting up an automatic pharmacist-initiated pharmacokinetic dosing service. Hosp Formul 1993;28:589–92.
22. Mousavi M, Dashti-Khavidaki S, Khalili H, et al. Impact of clinical pharmacy services on stress ulcer prophylaxis prescribing and related cost in patients with renal insufficiency. Int J Pharm Pract 2012;Nov 9.
23. Damaske DL, Baird RW. Development and implementation of a pharmacist managed inpatient warfarin protocol. Proc (Baylor Univ Med Cent) 2005;18:397–400.
24. Radley AS, Hall J, Farrow M, et al. Evaluation of anticoagulation control in a pharmacist operated anticoagulation clinic. J Clin Pathol 1995;48:545–47.
25. Pharmacy and Therapeutics Committee. Medication policies and protocols of Nebraska Methodist Hospital, Methodist Women’s Hospital.
26. University of Kentucky Pharmacy Services. Therapeutic interchanges [Internet]. Available at www.hosp.uky.edu/pharmacy/interchange.asp
27. Bayshore Community Hospital Department of Pharmacy. Conversion of intravenous azithromycin (Zithromax), ceftriaxone (Rocephin), ciprofloxacin (Cipro), fluconazole (Diflucan), lansoprazole (Prevacid), levofloxacin (Levaquin), linezolid (Zyvox), metronidazole (Flagyl), moxifloxacin (Avelox), potassium chloride (KC), or ranitidine (Zantac) to oral medication [Internet]. [cited 2013 May 9]. Available at www.ashp.org/s_ashp/docs/files/R-IVtoPOConvPol-2.pdf.
28. Medication Education Safety Approval Committee, Massachusetts General Hospital. Automatic intravenous to oral protocol [Internet]. MESAC memo; 2005 July [cited 2013 March 9]. Available at www2.massgeneral.org/pharmacy/mesac/mesac_memo3.pdf.
29. Hanson RL, Habibi M, Khamo N, et al. Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis. Am J Health Syst Pharm 2014;71:463–9.
30. Making pharmacists part of the multidisciplinary team. Hosp Case Manag 2014;22:13–6.
31. Preslaski CR, Lat I, MacLaren R, et al. Pharmacist contributions as members of the multidisciplinary ICU team. Chest 2013;144:1687–95.
32. Ripley TL, Adamson PB, Hennebry TA, et al. Collaborative practice model between cardiologists and clinical pharmacist for management of patients with cardiovascular disease in an outpatient clinic. Ann Pharmacother 2014;48:412–9.
33. Smith M, Bates DW, Bodenheimer TS. Pharmacists belong in accountable care organizations and integrated care teams. Health Aff (Millwood) 2013;32:1963–70.
34. Ukens C. New Jersey rewrites its state pharmacy practice act. Drug Topics 2004;148:41.
35. New Jersey Board of Pharmacy Laws. Statute 45:14-64. Inapplicability relative to collaborative drug therapy management in hospital. [Internet] July 2011 [cited 11 September 14]. Available from: www.njconsumeraffairs.gov/laws/pharmlaws.pdf.
36. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm 1999;56:347–79.
37. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy 2007;27:481–93.
38. Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy 2001;21:129–41.
